Although glioma cases have been divided into GBM and non-GBM classifications for discovering novel histological subtype-specific risk loci, glioma is increasingly being understood to have several distinctive molecular subtypes, such as IDH mutation, arm level 1p/19q co-deletion, and promoter mutation in the telomerase reverse transcriptase (TERT) gene4. This evidence concerns the gene TERT and central nervous system cancer.